Neurologists pass on Aduhelm again. Most agree with CMS decision to limit coverage, study finds
A majority of neurologists agree with Medicare on the need for more data on Biogen and Eisai’s Alzheimer’s disease med Aduhelm, despite FDA approval.
More than half (52%) of neurologists agree with the Centers for Medicare and Medicaid Services (CMS) proposed decision in January to limit coverage to patients in clinical trials, Spherix Global Insights’ latest study found. Only 15% disagreed with the decision, while the rest were neutral.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.